– The partnership will harness genetic and clinical data from millions of patients tested at Invitae (NVTA) and Deerfield's expertise in drug discovery to address high unmet needs among rare disease ...

Invitae’s revenue has climbed over time thanks to a vast portfolio of genetic tests. At the same time, the company has struggled to turn that into profitability. Invitae shares have dropped more than ...